Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL29684494 | 1.00 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL1818768 | 1.00 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL19900361 | 1.00 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL31198220 | 1.00 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL1815849 | 1.00 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| SCHEMBL1819631 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| SCHEMBL1818338 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| SCHEMBL27893120 | 0.96 | TSHR (0.53) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| SCHEMBL1723878 | 0.95 | TSHR (0.59) | TSHRALDH1A1TDP1MMP3MMP9 | |
| SCHEMBL3631759 | 0.95 | TSHR (0.59) | TSHRALDH1A1TDP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037560-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2018-02-08 | — | — | US | claimed |
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11225467-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20190263763-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10273219-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180037560-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-11225467-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-20190263763-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-20180037560-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-10273219-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.